Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Muvalaplin (LY3473329) in Healthy Subjects
NCT04472676Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of muvalaplin in elevated lipoprotein(a) (Lp(a)) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration. Started Aug 2020; status: completed.
02
Drugs
muvalaplin
03
Conditions
elevated lipoprotein(a) (Lp(a))
Beyond the preview
Go deeper on NCT04472676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04472676.